Targovax ASA logo

TRVX - Targovax ASA News Story

NOK8.05 0.4  4.6%

Last Trade - 3:25pm

Sector
Healthcare
Size
Micro Cap
Market Cap £49.3m
Enterprise Value £46.2m
Revenue £238k
Position in Universe 989th / 1784

BRIEF-Targovax granted US patent for mutant-ras neoantigen vaccines

Mon 25th September, 2017 6:00am
Sept 25 (Reuters) - TARGOVAX ASA  TRVX.OL  
    * REG-TARGOVAX GRANTED US PATENT FOR MUTANT-RAS NEOANTIGEN 
PLATFORM LEAD PRODUCTS 
    * PATENT PROTECTS TARGOVAX' MUTANT-RAS SPECIFIC NEOANTIGEN 
VACCINES, TG01 AND TG02, FOR THE TREATMENT OF 
CANCER IN COMBINATION WITH ANTI-METABOLITE CHEMOTHERAPY 
    * EXTENDS IP PROTECTION OF TG01 AND TG02 UNTIL MAY 6, 2034 
 
Source text for Eikon:  ID:nGNE3LhcKb  
Further company coverage:  TRVX.OL  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.